Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA,
J Neurooncol. 2014 Jul;118(3):557-99. doi: 10.1007/s11060-013-1339-4. Epub 2014 Apr 17.
What is the influence of targeted medical therapies on disease control and survival in the adult patient with progressive glioblastoma?
This recommendation applies to adult patients with progressive glioblastoma
Level III Treatment with bevacizumab is recommended as it provides improved disease control compared to historical controls as measured by best imaging response and progression free survival at 6 months. Given that there are a large number of therapies are available for progressive glioblastoma that may be applied under selected circumstances dependent on patient characteristics and treating physician judgment, it is strongly recommended that patients with progressive glioblastoma be enrolled in properly designed clinical investigations to provide convincing evidence of therapeutic value.
靶向药物治疗对进展性胶质母细胞瘤患者的疾病控制和生存的影响是什么？
本推荐适用于进展性胶质母细胞瘤的成年患者
贝伐珠单抗治疗是 III 级推荐，因为与历史对照相比，它可改善最佳影像学反应和 6 个月无进展生存期，从而改善疾病控制。鉴于有大量的治疗方法可用于进展性胶质母细胞瘤，这些方法可能根据患者的特征和治疗医生的判断，在特定情况下应用，强烈建议进展性胶质母细胞瘤患者入组适当设计的临床研究，以提供治疗价值的有力证据。
